Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
1-Minute Consult

Microscopic colitis: What is it, and what are the treatment options?

Katherine E. Westbrook, DO and Ari Garber, MD, EdD, MS, EdM
Cleveland Clinic Journal of Medicine April 2024, 91 (4) 215-216; DOI: https://doi.org/10.3949/ccjm.91a.23057
Katherine E. Westbrook
Department of Internal Medicine, Cleveland Clinic, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: [email protected]
Ari Garber
Department of Gastroenterology, Hepatology & Nutrition, Cleveland Clinic, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Find this author on Cleveland Clinic
  • Article
  • Info & Metrics
  • PDF
Loading

Microscopic colitis, an inflammatory disorder characterized by chronic diarrhea, is so named because its diagnosis requires histologic evaluation with mucosal biopsy. It may be overlooked as a cause of chronic diarrhea because cross-sectional imaging and endoscopic evaluation are usually normal in the absence of a microscopic evaluation. A standard approach to therapy improves symptoms and quality of life.

DIAGNOSTIC CONSIDERATIONS

Microscopic colitis has 2 subtypes: the collagenous subtype features the development of a subepithelial collagen band, and the lymphocytic subtype is characterized by intraepithelial lymphocytosis.1

The quintessential clinical presentation, regardless of the subtype, is chronic, nonbloody, watery diarrhea with concomitant urgency, abdominal pain, and weight loss. Likely causes are multifactorial and include the following:

  • Alteration of gut microbiota, or dysbiosis2

  • Immune system dysregulation

  • Medications such as proton pump inhibitors, selective serotonin reuptake inhibitors, nonsteroidal anti-inflammatory drugs, and checkpoint inhibitors2,3

  • Bile acid malabsorption

  • Smoking

  • Genetic susceptibility, with protective human leukocyte antigen loci implicated.2

Because the clinical presentation of microscopic colitis often overlaps with other diagnoses such as celiac disease and irritable bowel syndrome, competing diagnoses should be excluded.2 The diagnosis of microscopic colitis can be confirmed with colonoscopy with biopsy of the ascending and descending colon.

Despite the inflammatory nature of microscopic colitis, there is little benefit to obtaining C-reactive protein and erythrocyte sedimentation rate values, as neither is elevated in most cases of microscopic colitis.4

A recent meta-analysis determined the worldwide incidence of microscopic colitis to be about 5 per 100,000 patient-years, with a female predominance.2 Although microscopic colitis occurs at all ages, it is more common in patients older than 60.

TREATMENT: BUDESONIDE FOR INDUCTION AND MAINTENANCE OF CLINICAL REMISSION

First-line therapy for microscopic colitis, regardless of the subtype, is budesonide 9 mg/day for 8 weeks.5 If the patient is symptom-free after 8 weeks, budesonide therapy can be stopped. If the patient remains symptomatic at the end of 8 weeks or if symptoms recur, then budesonide can be continued or resumed at the lowest effective dose, usually 6 mg/day or less, for 6 to 12 months.2

Patients should be advised to avoid smoking and using nonsteroidal anti-inflammatory drugs. If possible, they should discontinue all associated medications, including proton pump inhibitors, statins, aspirin, immune checkpoint inhibitors, and selective serotonin reuptake inhibitors.3

Alternative therapies

When budesonide therapy is unfeasible or ineffective, other treatment options include secondary medications such as the bile acid sequestrant cholestyramine, loperamide, or bismuth salicylate, all with varying degrees of efficacy.4,5 Some authors note that starting loperamide with budesonide might augment symptomatic relief, but few studies suggest that this combination is superior to budesonide alone.4,5

Some evidence supports the use of immunomodulators, including azathioprine and mercaptopurine, in the treatment of microscopic colitis.2,6 Biologic therapies such as antitumor necrosis factor agents infliximab or adalimumab or the anti-integrin antibody agent vedolizumab have shown some success.2 Data are emerging regarding Janus kinase inhibitors for treating microscopic colitis, but to date their efficacy is uncertain.2 Mesalamine compounds have not proven effective. The American Gastroenterological Association Institute guideline5 recommends mesalamine as a potential alternative to budesonide, but the European guidelines7 do not.

Studies of probiotics have also generated little evidence to support their use in mitigating microscopic colitis.5 The Institute guideline and other authors recommend against the use of probiotics for microscopic colitis.4,5

DISEASE COURSE

With effective treatment, symptoms and quality of life improve with microscopic colitis. Predictions of sustained remission vary widely among studies.1 Although remission occurs for many patients, in most, the typical disease course is chronic or relapsing.8

As a general rule, continued budesonide therapy may be indicated for patients who are not in remission after 6 to 12 months.8 Unlike ulcerative colitis and Crohn disease, which carry a longitudinal risk of colorectal cancer, microscopic colitis carries no such increased risk. The goal of continued treatment is clinical (ie, symptomatic) remission.

DISCLOSURES

The authors report no relevant financial relationships which, in the context of their contributions, could be perceived as a potential conflict of interest.

  • Copyright © 2024 The Cleveland Clinic Foundation. All Rights Reserved.

REFERENCES

  1. ↵
    1. Lazenby AJ,
    2. Yardley JH,
    3. Giardiello FM,
    4. Jessurun J,
    5. Bayless TM
    . Lym-phocytic (‘microscopic’) colitis: a comparative histopathologic study with particular reference to collagenous colitis. Hum Pathol 1989; 20(1):18–28. doi:10.1016/0046-8177(89)90198-6
    OpenUrlCrossRefPubMed
  2. ↵
    1. Nielsen OH,
    2. Fernandez-Banares F,
    3. Sato T,
    4. Pardi DS
    . Microscopic colitis: etiopathology, diagnosis, and rational management. Elife 2022; 11:e79397. doi:10.7554/eLife.79397
    OpenUrlCrossRef
  3. ↵
    1. Tong J,
    2. Zheng Q,
    3. Zhang C,
    4. Lo R,
    5. Shen J,
    6. Ran Z
    . Incidence, prevalence, and temporal trends of microscopic colitis: a systematic review and meta-analysis [published correction appears in Am J Gastroenterol 2015; 110(7):1121]. Am J Gastroenterol 2015; 110(2):265–277. doi:10.1038/ajg.2014.431
    OpenUrlCrossRefPubMed
  4. ↵
    1. Pisani LF,
    2. Tontini GE,
    3. Marinoni B, et al
    . Biomarkers and microscopic colitis: an unmet need in clinical practice [published correction appears in Front Med (Lausanne) 2020; 7:4]. Front Med (Lausanne) 2017; 4:54. doi:10.3389/fmed.2017.00054
    OpenUrlCrossRef
  5. ↵
    1. Nguyen GC,
    2. Smalley WE,
    3. Vege SS,
    4. Carrasco-Labra A; Clinical Guidelines Committee
    . American Gastroenterological Association Institute guideline on the medical management of microscopic colitis. Gastroenterology 2016; 150(1):242–246. doi:10.1053/j.gastro.2015.11.008
    OpenUrlCrossRefPubMed
  6. ↵
    1. Ashraf MU,
    2. Aslam M,
    3. Zaheer MS,
    4. Rabbani MU,
    5. Khan SA,
    6. Ashraf J
    . Microscopic colitis: an overview. Interdiscip J Microinflammation 2014; 1:1. doi:10.4172/2381-8727.1000108
    OpenUrlCrossRef
  7. ↵
    1. Miehlke S,
    2. Guagnozzi D,
    3. Zabana Y, et al
    . European guidelines on microscopic colitis: United European Gastroenterology and European Microscopic Colitis Group statements and recommendations. United European Gastroenterol J 2021; 9(1):13–37. doi:10.1177/2050640620951905
    OpenUrlCrossRef
  8. ↵
    1. Tome J,
    2. Sehgal K,
    3. Kamboj AK, et al
    . Budesonide maintenance in microscopic colitis: clinical outcomes and safety profile from a population-based study. Am J Gastroenterol 2022; 117(8):1311–1315. doi:10.14309/ajg.0000000000001774
    OpenUrlCrossRef
PreviousNext
Back to top

In this issue

Cleveland Clinic Journal of Medicine: 91 (4)
Cleveland Clinic Journal of Medicine
Vol. 91, Issue 4
1 Apr 2024
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Microscopic colitis: What is it, and what are the treatment options?
(Your Name) has sent you a message from Cleveland Clinic Journal of Medicine
(Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Microscopic colitis: What is it, and what are the treatment options?
Katherine E. Westbrook, Ari Garber
Cleveland Clinic Journal of Medicine Apr 2024, 91 (4) 215-216; DOI: 10.3949/ccjm.91a.23057

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Microscopic colitis: What is it, and what are the treatment options?
Katherine E. Westbrook, Ari Garber
Cleveland Clinic Journal of Medicine Apr 2024, 91 (4) 215-216; DOI: 10.3949/ccjm.91a.23057
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Linkedin Share Button

Jump to section

  • Article
    • DIAGNOSTIC CONSIDERATIONS
    • TREATMENT: BUDESONIDE FOR INDUCTION AND MAINTENANCE OF CLINICAL REMISSION
    • DISEASE COURSE
    • DISCLOSURES
    • REFERENCES
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • What diagnostic tests should be done after discovering clubbing in a patient without cardiopulmonary symptoms?
  • Does my adult patient need a measles vaccine?
  • Do I need to treat supine hypertension in my hospitalized patient?
Show more 1-Minute Consult

Similar Articles

Subjects

  • Gastroenterology

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2025 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire